Discussion
A first-in-human trial testing Adjuvia Therapeutics‘ ATI-105 for Friedreich’s ataxia (FA) — an oral therapy derived from bacteria and engineered to cross a barrier protecting the brain — is now underway, having dosed its first participant. The Phase 1 study (NCT07869654), sponsored by the California-based biotech, is…
